Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas

Purpose: GSK3β is a protein kinase that can suppress a number of key oncoproteins. We have previously shown in preclinical models of pancreatic ductal adenocarcinoma (PDAC) that inhibition of GSK3β causes stabilization and nuclear translocation of β-catenin, poor differentiation, proliferation, and resistance to radiation. The objective of this study was to determine its utility as a biomarker of clinical outcomes. Experimental Design: Automated Quantitative Immunofluorescence Analysis (AQUA) of GSK3β was performed on a tissue microarray with samples from 163 patients treated on RTOG 9704. On the basis of findings in an exploratory cohort, GSK3β was analyzed as a categorical variable using its upper quartile (>Q3) as a cut point. Overall survival (OS) and disease-free survival (DFS) were estimated with the Kaplan–Meier method, and GSK3β groupings were compared using the log-rank test. Univariable and multivariable Cox proportional hazards models were used to determine associations between GSK3β and OS/DFS. Results: The 3-year OS rates for GSK3β≤Q3 versus GSK3β >Q3 were 16% (95% confidence intervals; CI, 10%–23%) and 30% (95% CI, 17%–44%), respectively, P = 0.0082. The 3-year DFS rates were 9% (95% CI, 5%–15%) and 20% (95% CI, 9%–33%) respectively, P value = 0.0081. On multivariable analysis, GSK3β was a significant predictor of OS. Patients with GSK3β >Q3 had a 46% reduced risk of dying of pancreatic cancer (HR, 0.54; 95% CI, 0.31–0.96, P value = 0.034). The HR for DFS was 0.65 (95% CI, 0.39–1.07; P value = 0.092). Conclusions: GSK3β expression is a strong prognosticator in PDAC, independent of other known factors such as tumor (T) stage, nodal status, surgical margins and CA19-9. Clin Cancer Res; 21(24); 5612–8. ©2015 AACR.

[1]  J. Yeh,et al.  GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB. , 2013, Cancer discovery.

[2]  Z. Shao,et al.  Expression of Dickkopf-1 and Beta-Catenin Related to the Prognosis of Breast Cancer Patients with Triple Negative Phenotype , 2012, PloS one.

[3]  A. Sauvanet,et al.  Prognostic factors for resectable pancreatic adenocarcinoma. , 2011, Journal of visceral surgery.

[4]  C. Tudur-Smith,et al.  Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer , 2011, British Journal of Cancer.

[5]  R. Abrams,et al.  Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial , 2011, Annals of Surgical Oncology.

[6]  M. Hebrok,et al.  KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma , 2010, Nature Reviews Cancer.

[7]  T. Giordano,et al.  GSK3β and β-Catenin Modulate Radiation Cytotoxicity in Pancreatic Cancer , 2010 .

[8]  K. Griffith,et al.  Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer. , 2009, International journal of radiation oncology, biology, physics.

[9]  Diane M Simeone,et al.  Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. , 2009, Cancer cell.

[10]  Jun Yu,et al.  Promoter methylation of the Wnt/β‐catenin signaling antagonist Dkk‐3 is associated with poor survival in gastric cancer , 2008, Cancer.

[11]  R. Abrams,et al.  Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Baldwin,et al.  Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. , 2008, Cancer research.

[13]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[14]  Giuseppe Garcea,et al.  Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. , 2008, JOP : Journal of the pancreas.

[15]  Xiao-mei Zhang,et al.  Altered distribution of β-catenin and prognostic roles in colorectal carcinogenesis , 2008, Scandinavian journal of gastroenterology.

[16]  J. Kench,et al.  Common Activation of Canonical Wnt Signaling in Pancreatic Adenocarcinoma , 2007, PloS one.

[17]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Terracciano,et al.  Prognostic significance of the wnt signalling pathway molecules APC, β‐catenin and E‐cadherin in colorectal cancer—a tissue microarray‐based analysis , 2007, Histopathology.

[19]  S. Leach,et al.  Wnt/β-catenin signaling is required for development of the exocrine pancreas , 2007, BMC Developmental Biology.

[20]  T. Smyrk,et al.  Aberrant Nuclear Accumulation of Glycogen Synthase Kinase-3β in Human Pancreatic Cancer: Association with Kinase Activity and Tumor Dedifferentiation , 2006, Clinical Cancer Research.

[21]  A. Bell,et al.  Aberrant Wnt/β-Catenin Signaling in Pancreatic Adenocarcinoma , 2006 .

[22]  D. Melton,et al.  β-Catenin is essential for pancreatic acinar but not islet development , 2005, Development.

[23]  W. Kaelin,et al.  The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. , 2005, Cancer cell.

[24]  M. Tsao,et al.  Epithelial-Cadherin and β-Catenin Expression Changes in Pancreatic Intraepithelial Neoplasia , 2004, Clinical Cancer Research.

[25]  Ying Qi,et al.  Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization* , 2003, Journal of Biological Chemistry.

[26]  James M. Roberts,et al.  Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. , 2003, Molecular cell.

[27]  C. Fenoglio-Preiser,et al.  Dysregulation of β-Catenin Expression Correlates With Tumor Differentiation in Pancreatic Duct Adenocarcinoma , 2003, Annals of Surgical Oncology.

[28]  D. Rimm,et al.  Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.

[29]  J. Cameron,et al.  Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. , 2002, The American journal of pathology.

[30]  D. Rimm,et al.  Tissue Microarray Analysis of β-Catenin in Colorectal Cancer Shows Nuclear Phospho-β-catenin Is Associated with a Better Prognosis , 2001 .

[31]  R. Moll,et al.  Analysis of β-Catenin Gene Mutations in Pancreatic Tumors , 1999, Digestion.

[32]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[33]  Valsamo Anagnostou,et al.  Antibody validation. , 2010, BioTechniques.

[34]  T. Giordano,et al.  GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. , 2010, Neoplasia.

[35]  D. Rimm,et al.  Automated analysis of tissue microarrays. , 2010, Methods in molecular biology.

[36]  A. Bell,et al.  Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. , 2006, Neoplasia.

[37]  D L Rimm,et al.  Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  R. Moll,et al.  Analysis of beta-catenin gene mutations in pancreatic tumors. , 1999, Digestion.

[39]  D.,et al.  Regression Models and Life-Tables , 2022 .